Top Markets
Coin of the day
Brickell Biotech, Inc. Brickell Biotech, Inc.

Brickell Biotech, Inc.

BBI
Rangering i aksjer #40377
Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical... Brickell Biotech, Inc. is a pharmaceutical company currently in the clinical development phase, dedicated to creating prescription medicines for various debilitating conditions, including autoimmune and inflammatory disorders, primarily within the United States. Its product pipeline includes sofpironium bromide, which has successfully finished Phase III clinical trials for treating excessive underarm sweating (primary axillary hyperhidrosis). Other notable candidates are BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent stimulator of interferon genes (STING) inhibitor, being explored for autoinflammatory and rare genetic illnesses. The company is also advancing next-generation kinase inhibitors. Brickell Biotech collaborates with several partners, such as Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. Established in 2009, its main office is located in Boulder, Colorado.
Aksjekurs
$2.35
Sist synkronisert: 2022-09-07
Markedsverdi
$162.94K
Endring (1 dag)
2.17%
Endring (1 år)
0.00%
Land
US
Handel Brickell Biotech, Inc. (BBI)

Kategori

P/S-forhold for Brickell Biotech, Inc. (BBI)
P/S-forhold per 2026 TTM: 0
Ifølge Brickell Biotech, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Brickell Biotech, Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE